NeuroBio
NeuroBio is a UK-based, preclinical stage biopharma startup developing therapeutics for Alzheimer's disease. Acetyl Choline Esterase (AChE) is the enzyme responsible for breaking down acetylcholine, which leads to disease progression in Alzheimer's. Neuro-Bio has identified a peptide derived from AChE and has a claim that this fragment is the main pathological driver in Alzheimer's disease, by acting in parts of the…
Funding snapshot
About
NeuroBio is a UK-based, preclinical stage biopharma startup developing therapeutics for Alzheimer's disease. Acetyl Choline Esterase (AChE) is the enzyme responsible for breaking down acetylcholine, which leads to disease progression in Alzheimer's. Neuro-Bio has identified a peptide derived from AChE and has a claim that this fragment is the main pathological driver in Alzheimer's disease, by acting in parts of the brain impacted in early disease stage. The company operates in the Genomics sector. Its business model centers on Theranostics. Founded in 2013, headquartered in Oxford, United Kingdom. The company has raised $14.1M at the Series A stage. Backed by investors including Kairos Ventures, The Porter Foundation Switzerland, Alcatt, P and S Yates, Roadknight Custodian and others.
Business model
Genomics > Applied Genomics > Clinical Genomics > Theranostics
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.